Geron (GERN) Stock Rises 40% In 2019 So Far: Here's Why
Zacks Investment Research | Aug 28, 2019 10:18PM ET
Geron Corporation (NASDAQ:GERN) shares have risen 40% so far this year against the industry ’s decrease of 3%, riding on the progress of its sole pipeline candidate, imetelstat.
Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis (“MF”) in a phase II IMbark study and myelodysplastic syndromes (“MDS”) in a phase II/III IMerge study.
Notably, both the studies are being conducted by Geron, following the termination of the collaboration related to imetelstat development by Johnson & Johnson (NYSE:JNJ) last year. The candidate enjoys orphan drug designation for both the indications.
Pipeline Progress
Geron is progressing well with the development of imetelstat. In May, the company completed the transfer of the sponsorship of the investigational new drug related to imetelstat from Janssen. Geron now holds the full responsibility for the development of imetelstat.
Enrollment has been stopped in the phase II portion of IMerge study and the company anticipates top-line data from it by the end of 2019. Preliminary data presented last year had shown that the benefit/risk profile of imetelstat in treated patients, including the expansion arm, supports continued development in lower risk MDS indication. Based on this data, the company initiated the phase III portion of the IMerge study earlier this month.
Geron has also added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat.
Meanwhile, the company postponed the date of the end of phase II meeting related to IMbark study to the first quarter of 2020 from the third quarter of this year. The extended period is likely to be used for further analysis of data from the IMbark study, which may support the regulatory application seeking approval of imetelstat in relapsed/refractory MF.
Although the company’s operating expense is set to increase due to cost of imetelstat development following the termination of collaboration with J&J, Geron has sufficient funds to start the phase III portion of IMerge studies.
However, dependence on a single pipeline candidate is a concern. Any hiccups in development of imetelstat may hurt Geron’s stock significantly. Meanwhile, Acceleron Pharma (NASDAQ:XLRN) and its partner Celgene’s (NASDAQ:CELG) luspatercept, which is being developed for MDS in a phase III study, may give competition to imetelstat.
Get The News You Want
Geron Corporation Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.